Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,167.53
(
0.44%
)
US TECH 100
26,530.07
(
0.25%
)
Dow Jones
49,466.82
(
1.24%
)
Brent Oil
109.71
(
-2.37%
)
Bitcoin
76,357.91
(
0.77%
)
News Focus
News Focus
Post# of 517664
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

crescentmotor

Send PM Follow Ignore
Followers 20
Posts 2314
Boards Moderated 0
Alias Born 12/13/2009

crescentmotor

Re: Doc328 post# 480871

Saturday, 01/18/2025 1:18:56 PM

Saturday, January 18, 2025 1:18:56 PM

Post# of 517664

He has lost >18 months by not starting a real phase 3 in mid 2023.



Total BS. The extraordinary results of the extended OLE data resolve all doubts regarding Blarcamesine efficacy. If they want to cover their arse, the regulatory agencies can, when they approve Blarcamesine for AD, require a follow-up confirmatory trial. No problem there whatsoever.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent AVXL News
More AVXL News